 |
|
Double-blind Evaluation of Reinforcing and Anorectic Actions of Weight Control MedicationsInteraction of Pharmacological and Behavioral Treatments
George E. Bigelow, PhD;
Roland R. Griffiths, PhD;
Ira Liebson, MD;
Julia E. Kaliszakn
Arch Gen Psychiatry. 1980;37(10):1118-1123.
Abstract
Within a behavioral self-management treatment program for overweight, 59 patients were randomly assigned to receive as an adjunct either dextroamphetamine sulfate, fenfluramine hydrochloride, or placebo in a double-blind procedure. Patients self-regulated their drug intake during a four-week medication period. Two types of behavioral-pharmacological interaction were observed: (1) drug assignment influenced participation in the behavioral treatment; and (2) drug assignment influenced the extent of medication self-administration. The dextroamphetamine group was superior in terms of behavioral treatment participation, extent of eating and exercise habit change, and weight loss. Self-administration of dextroamphetamine was most well-maintained—showing it to be a reinforcer—and self-administration of fenfluramine was suppressed below placebo levels. No patient taking either drug showed excessive drug intake, and all were, in fact, conservative in drug use. These data concerning relative reinforcing efficacy within a therapeutic medication setting are discussed in relation to data from animal models used to assess relative abuse liability of these drugs.
Author Affiliations
From the Department of Psychiatry, Baltimore City Hospitals (Drs Bigelow, Griffiths, and Liebson and Ms Kaliszak); and the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine (Drs Bigelow, Griffiths, and Liebson).
Footnotes
Accepted for publication Jan 15, 1980.
Reprint requests to Department of Psychiatry, Baltimore City Hospitals, Baltimore, MD 21224 (Dr Bigelow).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Abuse Liability Assessment of Tobacco Products Including Potential Reduced Exposure Products
Carter et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:3241-3262.
ABSTRACT
| FULL TEXT
Current and Potential Drugs for Treatment of Obesity
Bray and Greenway
Endocr Rev 1999;20:805-875.
ABSTRACT
| FULL TEXT
|
